← All trials
NCT06548997
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2021
- Primary completion
- Oct 20, 2022
- Completion date
- Oct 20, 2022
- First posted
- Aug 12, 2024
- Last posted
- Aug 14, 2024
- Enrollment
- 57
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gan and Lee Pharmaceuticals, USALead sponsor
- Gan and Lee Pharmaceuticals, USAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.